Publication: Re‐infection in COVID‐19: Do we exaggerate our worries?
dc.contributor.coauthor | Arslan, Yusuf | |
dc.contributor.coauthor | Akgül, Fethiye | |
dc.contributor.coauthor | Sevim, Bünyamin | |
dc.contributor.coauthor | Varol, Zeynep Sedef | |
dc.contributor.department | School of Medicine | |
dc.contributor.kuauthor | Tekin, Süda | |
dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
dc.date.accessioned | 2024-11-10T00:09:48Z | |
dc.date.issued | 2022 | |
dc.description.abstract | Background Protective long-term immunity following coronavirus disease 2019 (COVID-19) is unclear. The study evaluated the relationship between the vaccination status and risk factors in the re-infection of patients with a diagnosis of COVID-19 who reported to the Public Health Management System in a province in south-eastern Turkey. Methods Patients with positive results for the severe acute respiratory syndrome coronavirus 2 by the real-time reverse transcription polymerase chain reaction (RT-PCR) test in respiratory samples were defined as confirmed cases. Reinfection was diagnosed in cases with COVID-19 real-time RT-PCR positivity, with or without COVID-19-like symptoms, in at least 90 days after the first infection/disease. Results A total of 58 811 patients with the diagnosis of COVID-19 from March 11, 2020, to August 31, 2021, were included in the study. Re-infection was detected in 421 (0.07%) of all patients. The mean age of the cases was 38.0 +/- 16.0 years, and 51% of them were female. Eight (2.0%) of the cases resulted in death due to re-infection. No hospitalization or mortality was observed in fully vaccinated patients. Additionally, none of the mortal cases had completed the vaccination schedule. Conclusions We are concerned that the re-infection rates and mortality may increase due to new variant strains. Vaccination is the greatest weapon against progression to critical illness in re-infections, even with existing mutations. Therefore, it is important for those without a full vaccination schedule to be vaccinated, even if they have been previously infected. | |
dc.description.indexedby | WOS | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.issue | 6 | |
dc.description.openaccess | YES | |
dc.description.publisherscope | International | |
dc.description.sponsoredbyTubitakEu | N/A | |
dc.description.volume | 52 | |
dc.identifier.doi | 10.1111/eci.13767 | |
dc.identifier.eissn | 1365-2362 | |
dc.identifier.issn | 0014-2972 | |
dc.identifier.quartile | Q1 | |
dc.identifier.scopus | 2-s2.0-85127245521 | |
dc.identifier.uri | https://doi.org/10.1111/eci.13767 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/17171 | |
dc.identifier.wos | 772990000001 | |
dc.keywords | Coronavirus | |
dc.keywords | COVID-19 | |
dc.keywords | Re-infection | |
dc.keywords | SARS-CoV-2 | |
dc.keywords | Vaccination SARS-COV-2 | |
dc.language.iso | eng | |
dc.publisher | Wiley | |
dc.relation.ispartof | European Journal of Clinical Investigation | |
dc.subject | Medicine | |
dc.subject | General Internal | |
dc.subject | Medicine | |
dc.subject | Research Experimental | |
dc.title | Re‐infection in COVID‐19: Do we exaggerate our worries? | |
dc.type | Journal Article | |
dspace.entity.type | Publication | |
local.contributor.kuauthor | Tekin, Süda | |
local.publication.orgunit1 | SCHOOL OF MEDICINE | |
local.publication.orgunit2 | School of Medicine | |
relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isOrgUnitOfPublication.latestForDiscovery | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
relation.isParentOrgUnitOfPublication.latestForDiscovery | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e |